Day One Biopharmaceuticals (NASDAQ:DAWN) Stock Rating Reaffirmed by Wedbush

Wedbush reissued their outperform rating on shares of Day One Biopharmaceuticals (NASDAQ:DAWN - Free Report) in a report issued on Wednesday, RTT News reports. The firm currently has a $33.00 price target on the stock.

A number of other brokerages also recently commented on DAWN. Piper Sandler restated an overweight rating and issued a $40.00 target price on shares of Day One Biopharmaceuticals in a research note on Tuesday, March 26th. Oppenheimer reissued a market perform rating on shares of Day One Biopharmaceuticals in a research note on Tuesday, February 27th. JPMorgan Chase & Co. lifted their target price on Day One Biopharmaceuticals from $32.00 to $36.00 and gave the company an overweight rating in a research report on Monday. The Goldman Sachs Group dropped their price target on Day One Biopharmaceuticals from $50.00 to $44.00 and set a buy rating on the stock in a research report on Tuesday, February 27th. Finally, Needham & Company LLC lifted their price objective on Day One Biopharmaceuticals from $30.00 to $33.00 and gave the company a buy rating in a report on Wednesday. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the company's stock. Based on data from MarketBeat, Day One Biopharmaceuticals currently has an average rating of Moderate Buy and an average price target of $39.33.

Day One Biopharmaceuticals Price Performance

Shares of NASDAQ:DAWN traded down $1.45 during trading hours on Wednesday, hitting $15.19. 4,619,425 shares of the company's stock traded hands, compared to its average volume of 772,543. The firm has a market capitalization of $1.33 billion, a P/E ratio of -6.38 and a beta of -1.48. The business has a fifty day moving average price of $15.28 and a 200-day moving average price of $13.79. Day One Biopharmaceuticals has a 1 year low of $9.67 and a 1 year high of $17.85.

Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) last issued its earnings results on Monday, February 26th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.57) by ($0.07). As a group, equities analysts predict that Day One Biopharmaceuticals will post -2.66 earnings per share for the current year.

Insider Buying and Selling at Day One Biopharmaceuticals

In other Day One Biopharmaceuticals news, insider Samuel C. Blackman sold 20,000 shares of the stock in a transaction dated Tuesday, February 27th. The shares were sold at an average price of $16.11, for a total transaction of $322,200.00. Following the completion of the sale, the insider now directly owns 1,224,662 shares of the company's stock, valued at $19,729,304.82. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, insider Samuel C. Blackman sold 20,000 shares of the firm's stock in a transaction on Tuesday, February 27th. The stock was sold at an average price of $16.11, for a total value of $322,200.00. Following the completion of the sale, the insider now owns 1,224,662 shares of the company's stock, valued at approximately $19,729,304.82. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Charles N. York II sold 2,666 shares of the company's stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $15.25, for a total value of $40,656.50. Following the transaction, the chief financial officer now directly owns 277,754 shares in the company, valued at $4,235,748.50. The disclosure for this sale can be found here. Insiders have sold 55,781 shares of company stock worth $883,160 over the last quarter. Insiders own 8.40% of the company's stock.

Hedge Funds Weigh In On Day One Biopharmaceuticals

Hedge funds have recently made changes to their positions in the company. Arizona State Retirement System lifted its holdings in shares of Day One Biopharmaceuticals by 8.8% during the third quarter. Arizona State Retirement System now owns 12,363 shares of the company's stock worth $152,000 after purchasing an additional 995 shares during the period. Quintet Private Bank Europe S.A. boosted its position in Day One Biopharmaceuticals by 43.2% during the fourth quarter. Quintet Private Bank Europe S.A. now owns 3,313 shares of the company's stock worth $48,000 after purchasing an additional 1,000 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in Day One Biopharmaceuticals by 130.9% in the third quarter. China Universal Asset Management Co. Ltd. now owns 2,226 shares of the company's stock valued at $27,000 after purchasing an additional 1,262 shares during the period. Hennion & Walsh Asset Management Inc. increased its position in shares of Day One Biopharmaceuticals by 2.5% in the first quarter. Hennion & Walsh Asset Management Inc. now owns 59,289 shares of the company's stock valued at $979,000 after buying an additional 1,445 shares in the last quarter. Finally, Principal Financial Group Inc. raised its stake in shares of Day One Biopharmaceuticals by 9.7% during the 3rd quarter. Principal Financial Group Inc. now owns 17,781 shares of the company's stock worth $218,000 after buying an additional 1,569 shares during the period. 87.95% of the stock is owned by institutional investors and hedge funds.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.